Shows Main Header




  
 

Events

More Information Coming Soon

 

 

 


Past Events

OTSS Webinar - Regulatory Requirements for Ocular Biologics Development

Webinar Recording

Presentation Slides

Speaker:
Maria Rivera, PhD
Pharmacologist/Toxicologist, US FDA

Date and Time: Thursday, March 10, 2022 12:00 PM–1:30 PM

Coordinated global efforts over the last several decades have resulted in the development and adoption of alternatives to traditional animal tests for dermal hypersensitivity assessment. Following the adverse outcome pathway (AOP) framework, several new approach methodologies (NAMs) mapped to key molecular and cellular events in the AOP have been validated and combined to yield “defined approaches”, which were shown to provide superior performance to the existing animal tests when compared to human data for hazard and potency categorization. However, regulatory and industry needs extend beyond classification to deriving points of departure that will facilitate quantitative risk assessment. Next Generation Risk Assessment (NGRA) is an exposure-led, hypothesis-driven approach which integrates NAMs. This hypothetical skin allergy risk assessment case study of two consumer product exposures - 0.1% coumarin in a face cream and 1% coumarin in a deodorant – demonstrates the application of a skin allergy NGRA framework which incorporates the Skin Allergy Risk Assessment (SARA) Model. The SARA Model is a Bayesian approach which allows prediction of a human relevant point of departure (PoD) (the HRIPT dose with a 1% chance of sensitisation or ED01 [µg cm-2]) based upon any combination of HRIPT, LLNA, DPRA, KeratinoSens, h-CLAT or U-SENS data. Through incorporation of benchmark exposure information, the SARA Model can be used to calculate a risk metric for a consumer relevant exposure. This case study demonstrates how integrating a computational model and NAM data in a weight of evidence can build confidence in robust decision making.

 

Lighting in the Vivarium; The Spectrum and Intensity Is Crucial, The Source Is Not

Webinar Recording

Presentation Slides

Date and Time: February 23, 2022 at 2:00 PM–3:00 PM ET

The use of light-emitting diodes (LED) for vivarium lighting and in other laboratory spaces has come to the fore in the last several years, primarily driven by cost considerations, lower energy costs, and lessened environmental impact. However, as with any new technology, concerns have been raised about the light emitted from these devices, and confusion has arisen regarding the safety of their use in these environments. The purpose of this presentation is to present some fundamental information on lighting systems, the current safe lighting recommendations for vivariums, dispel the concerns for the use of LED for vivariums and provide anyone responsible for lighting to design the best systems for their vivariums or retrofit current facilities with this technology.


OTSS Reception Meeting

Presentation Slides

Date and Time: March 15, 2021, 4:15 PM–5:40 PM, EDT

  • This virtual meeting is open for ALL SOT meeting registrants
  • We will share OTSS updates and announce award winners
  • We also have a virtual social networking opportunity to connect with fellow ocular toxicologists at the end of the reception


Nonclinical Safety Toxicology Strategies for the Development of Novel Ocular Biotherapeutics

Date and Time: March 17, 2021, 2:45 PM–4:15 PM, EDT

  • Toxicokinetic modeling approaches to informing dose selection for intravitreal biotherapeutics. Seung-Wook Chung, Boehringer Ingelheim
  • Ocular inflammation in nonclinical intravitreal toxicity studies with biologics: types, timing and translatability. Helen Booler, Roche
  • Development of KSI-301, An Ultra High Molecular Weight Phosphorylcholine Biopolymer Antibody Conjugate for Treatment of Retinal Diseases by Intravitreal Administration. John Sinclair, Kodiak Sciences
  • Preclinical pearls for successful gene therapy development, Past and Future. Daniel Chung
  • Nonclinical Toxicology Strategies for Development of Novel Ocular Biotherapeutics. Theresa Chen, FDA


OTSS/MDCPSS Virtual Career Panel—SOT Mentoring Event

Webinar Recording | Presentation Slides

Date and Time: Monday, September 21, 2020, at 12:00 Noon–1:00 PM, EDT

The Ocular Toxicology Specialty Section (OTSS) and the Medical Device and Combination Product Specialty Section (MDCPSS) are holding a virtual career panel as a mentoring event for SOT members interested in career development within the ocular and medical device toxicology fields. The panel will consist of professionals at early, middle, and late stages of their career from Academia, Government, Industry, and Consulting. The panelists will introduce themselves, provide a brief overview of how they arrived at their current position, and address questions from the event moderators. Then the Q&A session will be opened to the audience to engage the panel on career advice, strategy, and goal setting. Please join MDCPSS for our upcoming virtual career panel.

Panelists: 

Academia

Government

Industry

Consulting

Mindy Reynolds
Washington College

Ron Brown
Risk Science Consortium

Hiromi Hosako
Alcon
Joel Cohen
Gradient Corp.
Neera Tewari-Singh
Michigan State Univ.
Alan Hood
US FDA

James Kleinedler
Boston Scientific

Andrea Rodrigues
Tox Strategies

 

Elissa Wong
US FDA

Bob Przygoda*
Johnson & Johnson
William Wustenberg
Mycroft Medical LLC

 

 

Ed Reverdy
Johnson & Johnson

 

*Retired